Featured Research

from universities, journals, and other organizations

Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease

Date:
August 28, 2011
Source:
European Society of Cardiology (ESC)
Summary:
The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction of cardiovascular events.

Researchers have presented results from the Homburg Cream and Sugar (HCS) at the European Society of Cardiology Congress 2011 in Paris. The study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction of cardiovascular events.

To facilitate the study, an oral metabolic test protocol was developed to assess triglyceride and glucose tolerance prospectively. The test consisted of an oral fat load (250 ml cream drink containing 75 g fat) followed by a glucose drink (250 ml water with 75 g glucose) three hours later. (Patients with medical treatment for diabetes received only the cream drink.) Two sets of measurements were taken: first, fasting and postprandial triglyceride (TG) concentrations; and second, insulin concentrations and glucose tolerance.

This sequential testing was performed in 514 consecutive patients with stable coronary artery disease (CAD) undergoing coronary angiography. Eighteen months later they were followed-up for assessment of the primary composite endpoint of cardiovascular death or hospitalisation for cardiovascular events.

Results of the study showed that the combined testing of postprandial glucose and triglyceride tolerance is feasible in clinical practice. However, a number of specific conclusions emerged, notably that in the total cohort postprandial TG concentrations did not correlate with the number of primary endpoint events; fasting TG levels were found to be predictive, but this association was lost in multivariate analysis.

However, both fasting and postprandial TG levels were strongly correlated with glucose metabolism: patients with normal glucose tolerance had lower fasting TGs and a lower absolute postprandial TG increase than those with impaired glucose metabolism (although the mean relative TG increase was comparable). Thus, in patients with normal glucose tolerance both fasting and postprandial TG levels were identified as independent markers for cardiovascular outcomes. In those with impaired glucose tolerance, however, postprandial TG levels did not predict outcomes.

"This is the first prospective study to assess postprandial triglycerides and glucose tolerance at the same time in a representative cohort of patients with coronary artery disease," said investigator Professor Ulrich Laufs from the from Saarland University Hospital, Homburg, Germany. "While the combined sequential test protocol did allow the prediction of cardiovascular outcomes in the total cohort of patients with CAD, we did find that in CAD patients with diabetes and impaired glucose tolerance, absolute fasting and postprandial TG levels were high but not independently predictive of cardiovascular outcomes. In contrast, in patients with CAD and normal glucose tolerance, both fasting and -- with superior risk prediction -- postprandial TG concentrations were independent markers for cardiovascular outcomes."

As background to the study Laufs noted that serum TG concentrations have long been associated with the risk of CVD. However, the extent of that association was unclear and inconsistent in study results. "It is a matter of current debate whether serum triglycerides represent an independent risk factor for CVD," he said, "and how these values might be interpreted in secondary prevention of CVD. The HCS study was set up to clarify this."


Story Source:

The above story is based on materials provided by European Society of Cardiology (ESC). Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology (ESC). "Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease." ScienceDaily. ScienceDaily, 28 August 2011. <www.sciencedaily.com/releases/2011/08/110828101802.htm>.
European Society of Cardiology (ESC). (2011, August 28). Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/08/110828101802.htm
European Society of Cardiology (ESC). "Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease." ScienceDaily. www.sciencedaily.com/releases/2011/08/110828101802.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins